BOSS update: Oesophageal cancer with Massimil...

Rome V was published ten years after Rome IV. Maura Corsetti, co-chair of the Rome V Bowel Disorders committee, joins Pradeep Mundre to discuss the relaxed IBS criteria, three new adult diagnoses, the split between research and clinical criteria, and why explaining a gut-brain di ...  Show more

Flares, surgery and the postpartum period. Mette Julsgaard and Pradeep Mundre on whether active disease or a JAK inhibitor is the bigger risk, starting upadacitinib at 28 weeks, acute severe colitis and when to operate, vaccinating infants exposed to biologics. 

Send us Fan MailIn this episode, we review the clinical presentation, screening guidelines, diagnosis and management of Barrett's Esophagus - one of the risk factors for developing Esophageal Adenocarcinoma. In our medicine minute, we discuss a landmark trial that transitioned tr ...  Show more

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? ...  Show more

Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he de ...  Show more

Host: Darryl S. Chutka, M.D., [@chutkaMD]

Guest: Tanios S. Bekaii-Saab, M.D.

Although esophageal cancer is not a common malignancy, when found it often has a poor prognosis. It’s about four times more likely to occur ...